Major Depressive Disorder (MDD) represents one of modern medicine’s most persistent paradoxes: despite decades of research and numerous treatment options, patient outcomes remain stubbornly suboptimal. As pharmaceutical companies and research institutions invest billions in developing novel MDD medicines, a critical question emerges: Can the current pipeline of innovations finally address the fundamental challenges in treating Read.